Pacific Biosciences of California
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Pacific Biosciences of California (PACB) | 510.07M | -3.88 | -8.32 | 0.00% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 117.8% below Morningstar's fair value estimate.
Fair value
Pacific Biosciences of California Inc earns a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 45% discount to our quantitative fair value estimate of $3.55 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's liquidity strengthens our valuation estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. Reflecting the firm's liquidity is its median trading volume over the past 60 days, which ranks in the top 10% globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.
Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 23.3%, for example, ranks in the bottom 30% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the company's weak financial health rating could portend bankruptcy risk if economic conditions weaken.
By Quantitative Equity Report
Quote time 2026-11-20 19:52:58 · For reference only, not investment advice and not tailored to your situation.
Pacific Biosciences of California discussion 0 comments